The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. A comparison of immediate percutaneous coronary ...
The benefit of complete revascularization in older patients (≥75 years of age) with myocardial infarction and multivessel disease remains unclear. In this multicenter, randomized trial, we assigned ...
The advent of thrombolytic therapy initiated the era of pharmacologic reperfusion in the acute phase of myocardial infarction (MI). Although it was a major improvement in the treatment of acute MI ...
Final follow-up from the trial shows durable protection against TLF, especially in chronic total occlusions and diffuse long ...
PCI reduces angina frequency in stable coronary artery disease regardless of age, with older patients deriving the greatest ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The Time to Integrilin Therapy in Acute Myocardial Infarction—Thrombolysis in Myocardial Infarction (TITAN-TIMI 34) results were presented by Dr C Michael Gibson (Brigham and Women's Hospital, Boston, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results